Screening for diminished ovarian reserve in Portugal: a cost-saving answer to shorten the fertility journey-Reference-Cited by-同舟云学术

Screening for diminished ovarian reserve in Portugal: a cost-saving answer to shorten the fertility journey

Published:2023-07 Issue:7 Volume:12 Page:
ISSN:2042-6305
Container-title:Journal of Comparative Effectiveness Research
language:en
Short-container-title:J. Comp. Eff. Res.

Author:

Xavier Pedro¹,Dantas Sofia²,Almeida-Santos Teresa³,Soares Sérgio Reis⁴,Imhoff Ryan J⁵^ORCID,Genovez Victória⁶,Modesto Cátia⁷,Gens Helena⁸,Correia Inês⁹,Catalão Carlos¹⁰

Affiliation:

1. President of the Portuguese Society of Reproductive Medicine (SPMR); Gynaecology-Obstetrics specialist, sub-speciality in Reproductive Medicine, Centre for Reproduction Genetics Prof. Alberto Barros, 4100-021, Portugal

2. Gynaecology-Obstetrics specialist, sub-speciality in Reproductive Medicine, Hospital Senhora da Oliveira, Guimarães, 4835-044, Portugal

3. Gynaecology-Obstetrics specialist, sub-speciality in Reproductive Medicine, Centro Hospitalar Universitário de Coimbra (CHUC), Coimbra, 3004-561, Portugal

4. Gynaecology-Obstetrics specialist, sub-speciality in Reproductive Medicine, IVI (Instituto Valenciano de Infertilidade), Lisbon, 1800-282, Portugal

5. Research Scientist II, CTI Clinical Trial & Consulting Services, Covington, KY 41011, USA

6. Market Access Associate II, CTI Clinical Trial & Consulting Services Portugal, Lisbon, 1072-274, Portugal

7. HTA & Market Access Associate II, CTI Clinical Trial & Consulting Services Portugal, Lisbon, 1070-274, Portugal

8. Medical Affairs Lead, Roche Sistemas de Diagnósticos, Amadora, 2720-413, Portugal

9. Medical Science Liaison, Roche Sistemas de Diagnósticos, Amadora, 2720-413, Portugal

10. Access & Innovation Director, Roche Sistemas de Diagnósticos, Amadora, 2720-413, Portugal

Abstract

Aim: Assess the budget impact of nationwide screening for diminished ovarian reserve (OR), via anti-Müllerian hormone (AMH) levels, to the Portugal National Health System (NHS). Patients & methods: The clinical journey was determined using literature and the family planning decision-making process/response using survey results. A panel of four local clinicians validated all assumptions/inputs. Results: Screening for OR led to an expected savings of € 9.4 million for the NHS, driven by a 24% reduction in medically assisted reproduction (MAR) use. When needed, referral for MAR was earlier and more women used first-line versus second-line techniques. The model estimated a 12% decrease in failure. Conclusion: This model shows AMH screening may allow more informed decisions, leading to a shorter fertility journey, more efficient use of treatments, and substantial cost-savings for the NHS.

Publisher

Becaris Publishing Limited

Subject

Health Policy

Link

https://becarispublishing.com/doi/pdf/10.57264/cer-2023-0003

Reference38 articles.

1. Pordata. Idade média da mãe ao nascimento do primeiro filho. INE - Indicadores Demográficos Fontes de Dados. www.pordata.pt/portugal/idade+media+da+mae+ao+nascimento+do+primeiro+filho-805 (2020).

2. Birth rate by country - Thematic Map - Europe. https://www.indexmundi.com/map/?v=25&r=eu&l=en (2020).

3. Pordata. Saldos populacionais anuais: total natural e migratório. INE - Estatísticas de Nados-Vivos; INE - Estimativas Anuais da População Residente; INE - Estatísticas de Óbitos Fontes de Dados. www.pordata.pt/portugal/saldos+populacionais+anuais+saldo+total++saldo+natural+e+saldo+migratorio-657 (2020).

4. Conselho Nacional De Procriação Medicamente Assistida (CNPMA). Relatório - Atividade Desenvolvida pelos Centros de PMA em 2017. www.cnpma.org.pt/cnpma/Paginas/Relatorios-da-Atividade-em-pma.aspx (2021).

5. ESHRE. Factsheet on ART. www.eshre.eu/Europe/Factsheets-and-infographics (2020).